CliffBio
small molecule

ZANAFLEX

TIZANIDINE HYDROCHLORIDE

Loss of exclusivity—loss of exclusivity
CompanyLEGACY PHARMA INC SEZC

Drug detail

Brand nameZANAFLEX
Active ingredientTIZANIDINE HYDROCHLORIDE
StrengthEQ 2MG BASE
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalAugust 2002
Marketing statusRX

More from LEGACY PHARMA INC SEZC

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

ZANAFLEX patent cliff — loss of exclusivity — | CliffBio